In 2008 the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) joined forces to present the first edition of a biennial meeting addressing the scientific and educational needs of healthcare professionals treating malignant lung diseases. Now, following the success of the first two events, and on behalf of both societies, it gives us great pleasure to introduce the 3rd European Lung Cancer Conference (ELCC), 18–21 April 2012 in Geneva, Switzerland. We believe that a regular meeting on the topic of lung cancer plays a vital role in providing an updated overview of prevention, screening, diagnosis, treatment modalities and results of basic, clinical and translational research. This event should foster and enable fruitful interaction at a multidisciplinary level in order to strengthen an integrated approach to diagnosis and treatment of lung cancer.
We encourage you to save the date of this important European Conference and look forward to welcoming
you to Geneva in 2012.

Who should attend
Organized by top academic experts in lung cancer and thoracic malignancies, this Conference is relevant
for medical oncologists, radiotherapists, thoracic surgeons, respiratory physicians and other clinicians involved
in the diagnosis, treatment and follow-up of patients with lung cancer.

Learning objectives
* To analyze and interpret effectively the increasing amount of new clinical data available for multidisciplinary
* treatment decisions in patients with lung cancer and other thoracic malignancies.
* To determine the optimal roles of new diagnostics and therapeutics in clinical scenarios for the treatment of patients with early, locally-advanced and metastatic disease.
* To evaluate the roles of biological markers, specific gene mutations and pathological determinants in the development of optimal treatment strategies for systemic therapy of lung cancer patients.

Benefits in attending
This is THE thoracic CME conference that you should attend: Lung cancer specialists from a wide range of disciplines will share information on the latest developments in basic, clinical and translational research.
* Interaction between the audience and faculty will ensure that the data presented will be put into perspective for clinical practice. The format will include numerous real clinical-world decision questions.
* Sessions with debates on important controversial topics presented by the world’s leading authorities on the subjects.
* Meet-the-Expert sessions will provide additional opportunities to interact with the faculty. Topics will focus on issues that clinicians face in their daily practice.
* Specific workshops designated for certain oncology specialties with the overall Conference highlighting and focusing on the need for multidisciplinary collaboration

CME accreditation
The Conference program will be:
* Accredited with ESMO-MORA category 1 points.
* Submitted for CME accreditation to the ACOE (Accreditation Council for Oncology in Europe). ACOE accreditation has been endorsed by the Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS).
These credits are also recognized by the American Medical Association (AMA) as Physician’s Recognition Award (AMA PRA category 1 credits).
* Submitted for CME credit EBAP (European Board for Accreditation in Pneumology). EBAP accreditation has been endorsed by the Accreditation Council of Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS).

Location